RETRACTED: Protein Tyrosine Phosphatase Non-Receptor 11 (<i>PTPN11</i>/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).

Int J Mol Sci · 2023 · PMC10341803 · PMID 37445722

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

H661 cells had a significant decrease in their cellular viability following a combination treatment with SHPi + refametinib (S + R) of 42.26 ± 13.13% ( p = 0.0341) compared to the vehicle control (VC), and although it was not significant, showed a trend of increased sensitivity compared to refametinib alone (31.86 ± 7.74%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

RETRACTED: Protein Tyrosine Phosphatase Non-Receptor 11 (&lt;i&gt;PTPN11&lt;/i&gt;/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).

The sentences

RETRACTED: Protein Tyrosine Phosphatase Non-Receptor 11 (<i>PTPN11</i>/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).